For more information about this release, please scroll to bottom.
NEW YORK, May 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Zoetis Inc. (NYSE: ZTS), Aetna Inc. (NYSE: AET) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2260-100free.
Regeneron Pharmaceuticals, Inc. Analyst Notes
On May 5, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) issued a press release announcing a collaboration with Avalanche Biotechnologies, Inc., to discover, develop next-generation gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular BioFactory™, an adeno-associated virus-based, proprietary, next-generation platform for the discovery and development of gene therapy vectors for ophthalmology. As per the agreement, Regeneron has a time-limited right of first negotiation for certain rights to AVA-101, Avalanche's gene therapy product targeting vascular endothelial growth factor currently under development for the treatment of wet age-related macular degeneration, after the completion of the ongoing Phase IIa trial. Avalanche will get an upfront cash payment, contingent payments of up to $640 million upon achievement of certain development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products. The full analyst notes on Regeneron are available to download free of charge at:
Thermo Fisher Scientific, Inc. Analyst Notes
On May 6, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced that the Company will participate in the Bank of America Merrill Lynch 2014 Health Care Conference on May 13, 2014, at 10:40 a.m. (PDT) at the Encore at Wynn Las Vegas, in Las Vegas, Nevada. Marc N. Casper, Company President and CEO, will be present at the conference. The full analyst notes on Thermo Fisher are available to download free of charge at:
Zoetis Inc. Analyst Notes
On May 6, 2014, animal health Company - Zoetis Inc. (Zoetis) announced its financial results for Q1 2014. Revenue during the quarter was reported at $1.1 billion, up 0.6% YoY. According to Zoetis, revenue reflected an operational increase of 4%, with foreign currency having a negative impact of 3 percentage points. Net income attributable to Zoetis for Q1 2014 came in at $155 million, or $0.31 per diluted share, versus $140 million, or $0.28 per diluted share in Q1 2013. Adjusted net Income was $191 million, or adjusted diluted EPS of $0.38. Analysts surveyed by Thomson Reuters expected the Company to report earnings of $0.37 per share for Q1 2014. For full-year 2014, Zoetis reaffirmed its reported diluted EPS financial guidance between $1.15 and $1.21 per share (adjusted EPS between $1.48 to $1.54 per share) and revenues between $4.65 billion to $4.75 billion. The full analyst notes on Zoetis are available to download free of charge at:
Aetna Inc. Analyst Notes
On May 6, 2014, Aetna Inc. (Aetna) announced that the Company was recognized by DiversityInc as one of its Top 50 Companies for Diversity, ranking 19th on this year's list. According to DiversityInc, Aetna demonstrated outstanding credentials in all four areas of diversity management, namely, CEO commitment; talent pipeline; talent development, and supplier diversity. Grace Figueredo, Aetna's Vice President of Workplace Culture and Chief Diversity & Inclusion Officer, commented, "At Aetna, we believe that a strong, diverse company is one that ensures its employees can realize their full potential and aspire to be all that they can be." The full analyst notes on Aetna are available to download free of charge at:
GlaxoSmithKline plc Analyst Notes
On April 30, 2014, global healthcare group, GlaxoSmithKline plc (GSK) announced its financial results for Q1 2014. The Company posted 13.3% YoY decline in total turnover during the quarter to £5.6 billion. According to the Company, pharmaceutical and vaccines sales grew in all major regions, except the U.S. Profit attributable to shareholders for Q1 2014 came in at £719 million, or 13.7 pence per diluted share, as compared to £1.0 billion, or 19.6 pence per diluted share in Q1 2013. The Company reported that core EPS of 21.0 pence was driven by operating leverage and financial efficiencies. Analysts, on average, had forecast turnover of £5.84 billion and core EPS, which excludes certain items, of 20.7 pence, according to Thomson Reuters. For full-year 2014, GSK reiterated its core EPS growth of 4% and 8%, at constant exchange rates. The full analyst notes on GSK are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review